Emerging nano-formulations and nanomedicines applications for ocular drug delivery

Dawin Khiev; Zeinab A. Mohamed; Riddhi Vichare; Ryan Paulson; Sofia Bhatia; Subhra Mohapatra; Glenn P. Lobo; Mallika Valapala; Nagaraj Kerur; Christopher L. Passaglia; Shyam S. Mohapatra; Manas R. Biswal

doi:10.3390/nano11010173

Emerging nano-formulations and nanomedicines applications for ocular drug delivery

Dawin Khiev, Zeinab A. Mohamed, Riddhi Vichare, Ryan Paulson, Sofia Bhatia, Subhra Mohapatra, Glenn P. Lobo, Mallika Valapala, Nagaraj Kerur, Christopher L. Passaglia, Shyam S. Mohapatra, Manas R. Biswal

Research output: Contribution to journal › Review article › peer-review

113 Scopus citations

Abstract

Ocular diseases can deteriorate vision to the point of blindness and thus can have a major impact on the daily life of an individual. Conventional therapies are unable to provide absolute therapy for all ocular diseases due to the several limitations during drug delivery across the blood-retinal barrier, making it a major clinical challenge. With recent developments, the vast number of publications undergird the need for nanotechnology-based drug delivery systems in treating ocular diseases. The tool of nanotechnology provides several essential advantages, including sustained drug release and specific tissue targeting. Additionally, comprehensive in vitro and in vivo studies have suggested a better uptake of nanoparticles across ocular barriers. Nanoparticles can overcome the blood-retinal barrier and consequently increase ocular penetration and improve the bioavailability of the drug. In this review, we aim to summarize the development of organic and inorganic nanoparticles for ophthalmic applications. We highlight the potential nanoformulations in clinical trials as well as the products that have become a commercial reality.

Original language	English (US)
Article number	173
Pages (from-to)	1-19
Number of pages	19
Journal	Nanomaterials
Volume	11
Issue number	1
DOIs	https://doi.org/10.3390/nano11010173
State	Published - Jan 12 2021
Externally published	Yes

Bibliographical note

Funding Information:
Funding: This research was funded by NIH/NEI award EY027013-02 and USF Taneja College of Pharmacy New Faculty Development award to Manas R. Biswal.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Clinical trials
Ophthalmic applications
Organic and inorganic nanoparticles

Publisher link

10.3390/nano11010173

Find It

Find It at U of M Libraries

Cite this

@article{3e85b240dfa24911976b044c4a11bbaf,

title = "Emerging nano-formulations and nanomedicines applications for ocular drug delivery",

abstract = "Ocular diseases can deteriorate vision to the point of blindness and thus can have a major impact on the daily life of an individual. Conventional therapies are unable to provide absolute therapy for all ocular diseases due to the several limitations during drug delivery across the blood-retinal barrier, making it a major clinical challenge. With recent developments, the vast number of publications undergird the need for nanotechnology-based drug delivery systems in treating ocular diseases. The tool of nanotechnology provides several essential advantages, including sustained drug release and specific tissue targeting. Additionally, comprehensive in vitro and in vivo studies have suggested a better uptake of nanoparticles across ocular barriers. Nanoparticles can overcome the blood-retinal barrier and consequently increase ocular penetration and improve the bioavailability of the drug. In this review, we aim to summarize the development of organic and inorganic nanoparticles for ophthalmic applications. We highlight the potential nanoformulations in clinical trials as well as the products that have become a commercial reality.",

keywords = "Clinical trials, Ophthalmic applications, Organic and inorganic nanoparticles",

author = "Dawin Khiev and Mohamed, {Zeinab A.} and Riddhi Vichare and Ryan Paulson and Sofia Bhatia and Subhra Mohapatra and Lobo, {Glenn P.} and Mallika Valapala and Nagaraj Kerur and Passaglia, {Christopher L.} and Mohapatra, {Shyam S.} and Biswal, {Manas R.}",

note = "Funding Information: Funding: This research was funded by NIH/NEI award EY027013-02 and USF Taneja College of Pharmacy New Faculty Development award to Manas R. Biswal. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jan,

day = "12",

doi = "10.3390/nano11010173",

language = "English (US)",

volume = "11",

pages = "1--19",

journal = "Nanomaterials",

issn = "2079-4991",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Emerging nano-formulations and nanomedicines applications for ocular drug delivery

AU - Khiev, Dawin

AU - Mohamed, Zeinab A.

AU - Vichare, Riddhi

AU - Paulson, Ryan

AU - Bhatia, Sofia

AU - Mohapatra, Subhra

AU - Lobo, Glenn P.

AU - Valapala, Mallika

AU - Kerur, Nagaraj

AU - Passaglia, Christopher L.

AU - Mohapatra, Shyam S.

AU - Biswal, Manas R.

N1 - Funding Information: Funding: This research was funded by NIH/NEI award EY027013-02 and USF Taneja College of Pharmacy New Faculty Development award to Manas R. Biswal. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/1/12

Y1 - 2021/1/12

N2 - Ocular diseases can deteriorate vision to the point of blindness and thus can have a major impact on the daily life of an individual. Conventional therapies are unable to provide absolute therapy for all ocular diseases due to the several limitations during drug delivery across the blood-retinal barrier, making it a major clinical challenge. With recent developments, the vast number of publications undergird the need for nanotechnology-based drug delivery systems in treating ocular diseases. The tool of nanotechnology provides several essential advantages, including sustained drug release and specific tissue targeting. Additionally, comprehensive in vitro and in vivo studies have suggested a better uptake of nanoparticles across ocular barriers. Nanoparticles can overcome the blood-retinal barrier and consequently increase ocular penetration and improve the bioavailability of the drug. In this review, we aim to summarize the development of organic and inorganic nanoparticles for ophthalmic applications. We highlight the potential nanoformulations in clinical trials as well as the products that have become a commercial reality.

AB - Ocular diseases can deteriorate vision to the point of blindness and thus can have a major impact on the daily life of an individual. Conventional therapies are unable to provide absolute therapy for all ocular diseases due to the several limitations during drug delivery across the blood-retinal barrier, making it a major clinical challenge. With recent developments, the vast number of publications undergird the need for nanotechnology-based drug delivery systems in treating ocular diseases. The tool of nanotechnology provides several essential advantages, including sustained drug release and specific tissue targeting. Additionally, comprehensive in vitro and in vivo studies have suggested a better uptake of nanoparticles across ocular barriers. Nanoparticles can overcome the blood-retinal barrier and consequently increase ocular penetration and improve the bioavailability of the drug. In this review, we aim to summarize the development of organic and inorganic nanoparticles for ophthalmic applications. We highlight the potential nanoformulations in clinical trials as well as the products that have become a commercial reality.

KW - Clinical trials

KW - Ophthalmic applications

KW - Organic and inorganic nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85099309970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099309970&partnerID=8YFLogxK

U2 - 10.3390/nano11010173

DO - 10.3390/nano11010173

M3 - Review article

C2 - 33445545

AN - SCOPUS:85099309970

SN - 2079-4991

VL - 11

SP - 1

EP - 19

JO - Nanomaterials

JF - Nanomaterials

IS - 1

M1 - 173

ER -

Emerging nano-formulations and nanomedicines applications for ocular drug delivery

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this